-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Zevra Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2013 to 2023.
- Zevra Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$19.9M, a 674% decline year-over-year.
- Zevra Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$66.8M, a 301% decline year-over-year.
- Zevra Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$46M, a 72% decline from 2022.
- Zevra Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$26.8M, a 213% decline from 2021.
- Zevra Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$8.56M, a 33% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)